Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian Jackisch

Showing results (81-90 of 231) with videos related to

Pageof 24
Sort By:
Breast Care (Basel, Switzerland)|May 4, 2012
ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011Christoph Thomssen, Norbert Marschner, Michael Untch, et al.
Breast Cancer Research and Treatment|December 29, 2015
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceOtto Metzger-Filho, Evandro de Azambuja, Marion Procter, et al.
Journal of the National Cancer Institute|July 18, 2013
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Discussion of ABC7 Consensus and German RecommendationsMichael Untch, Nina Ditsch, Peter A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trialMarcus Schmidt, Ulrike Nitz, Toralf Reimer, et al.
Journal of the National Cancer Institute|March 4, 2014
ResponseVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|April 19, 2024
ABC7 Consensus: Assessment by a German Group of ExpertsNina Ditsch, Michael Untch, Peter A Fasching, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast Care (Basel, Switzerland)|May 8, 2014
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German PerspectiveNadia Harbeck, Norbert Marschner, Michael Untch, et al.
Breast Cancer Research and Treatment|September 20, 2020
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
Pageof 24

Showing results (81-90 of 231) with videos related to

Sort By:
Pageof 24
Breast Care (Basel, Switzerland)|May 4, 2012
ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011Christoph Thomssen, Norbert Marschner, Michael Untch, et al.
Breast Cancer Research and Treatment|December 29, 2015
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experienceOtto Metzger-Filho, Evandro de Azambuja, Marion Procter, et al.
Journal of the National Cancer Institute|July 18, 2013
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Geburtshilfe Und Frauenheilkunde|May 31, 2024
Discussion of ABC7 Consensus and German RecommendationsMichael Untch, Nina Ditsch, Peter A Fasching, et al.
European Journal of Cancer (Oxford, England : 1990)|October 5, 2023
Adjuvant capecitabine versus nihil in older patients with node-positive/high-risk node-negative early breast cancer receiving ibandronate - The ICE randomized clinical trialMarcus Schmidt, Ulrike Nitz, Toralf Reimer, et al.
Journal of the National Cancer Institute|March 4, 2014
ResponseVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Breast Care (Basel, Switzerland)|April 19, 2024
ABC7 Consensus: Assessment by a German Group of ExpertsNina Ditsch, Michael Untch, Peter A Fasching, et al.
Cancers|October 27, 2022
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled AnalysisSandra M Swain, Harrison Macharia, Javier Cortes, et al.
Breast Care (Basel, Switzerland)|May 8, 2014
Second International Consensus Conference on Advanced Breast Cancer (ABC2), Lisbon, 11/09/2013: The German PerspectiveNadia Harbeck, Norbert Marschner, Michael Untch, et al.
Breast Cancer Research and Treatment|September 20, 2020
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)Noam Pondé, Dominique Agbor-Tarh, Lissandra Dal Lago, et al.
Pageof 24